T. Rowe Price Associates’s CorMedix CRMD Stock Holding History

T. Rowe Price Associates’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$488K	Buy	62,054 +11,924	+24%	+$94.2K	﹤0.01%	2639
2026 Q1	$341K	Buy	50,130 +7,584	+18%	+$56.1K	﹤0.01%	2624
2025 Q4	$495K	Buy	42,546 +3,271	+8%	+$36.2K	﹤0.01%	2397
2025 Q3	$457K	Buy	39,275 +7,167	+22%	+$86.7K	﹤0.01%	2395
2025 Q2	$396K	Buy	32,108 +5,422	+20%	+$59.9K	﹤0.01%	2411
2025 Q1	$165K	Buy	26,686 +3,241	+14%	+$33.5K	﹤0.01%	2710
2024 Q4	$190K	Buy	23,445 +5,030	+27%	+$50.2K	﹤0.01%	2705
2024 Q3	$149K	Buy	18,415 +2,334	+15%	+$12.6K	﹤0.01%	2749
2024 Q2	$70K	Buy	16,081 +1,446	+10%	+$7.35K	﹤0.01%	2804
2024 Q1	$63K	Buy	14,635 +2,562	+21%	+$8.88K	﹤0.01%	2843
2023 Q4	$46K	Hold	12,073	–	–	﹤0.01%	2816
2023 Q3	$45K	Buy	+12,073	New	+$48K	﹤0.01%	2789
2021 Q4	–	Sell	-17,527	Closed	-$82K	–	2993
2021 Q3	$82K	Hold	17,527	–	–	﹤0.01%	2870
2021 Q2	$120K	Buy	17,527 +912	+5%	+$7.26K	﹤0.01%	2820
2021 Q1	$166K	Buy	+16,615	New	+$175K	﹤0.01%	2727

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

T. Rowe Price Associates's CRMD Position: Q2 2026 in Review

T. Rowe Price Associates increased its CorMedix (CRMD) stake by 24% in Q2 2026, buying an estimated $94.2K and bringing the position to 62,054 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

T. Rowe Price Associates first reported a position in CRMD in Q1 2021 and has held it in 15 quarters since. The position peaked at $495K in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

T. Rowe Price Associates held 62,054 shares of CorMedix worth $488K as of Q2 2026.
T. Rowe Price Associates bought 11,924 CorMedix shares in Q2 2026, an estimated $94.2K.
CorMedix made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2639 holding.
T. Rowe Price Associates first reported a position in CorMedix in Q1 2021 and has held it in 15 quarters since.
T. Rowe Price Associates's CorMedix position peaked at $495K in Q4 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.